Revenue was up 31% during the quarter and the gross margin rate improved 230 bps to 53.8% of sales.
The company sees Q2 revenue of $178M to $183M vs. $176M consensus and EPS of $0.58 to $0.63 vs. $0.61 consensus. Full-year guidance is for revenue of $650M to $665M and EPS of $1.65 to $1.75.
Wunderlich lowered its rating on NTRI to Hold on concerns over near-term catalysts.
Previously: Nutrisystem beats by $0.08, beats on revenue (April 26)
NTRI +1.17% premarket to $56.20.,